Corporate Governance at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportBoard of DirectorsOur...
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportBoard of DirectorsOur...
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents...
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider...
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Calgary, Alberta--(Newsfile Corp. - December 18, 2023) - The Newly Institute ("Newly" or the "Company") is pleased to report the...
Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,...
VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing...
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located...
BRENTWOOD, TN / ACCESSWIRE / December 5, 2023 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and...
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)...
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential...
Intrepid Recovery Center's Founder, John Nash Pakel, Champions the Next Phase in Addiction Treatment with the Introduction of PHP -...
BayMark's Study Demonstrates the Path to More Successful Opioid Use Disorder TreatmentLEWISVILLE, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- BayMark,...
BRENTWOOD, TN / ACCESSWIRE / November 28, 2023 / Odyssey Behavioral Healthcare, a leading provider of mental health, eating disorder,...
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,...
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite...
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products...
Cedar Recovery Expands Leadership with Dr. Stuart Ross as Medical Director for Cookeville Office, Bringing Extensive Addiction Medicine Expertise and...
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,...